Figure 3.

Extended CVD Risk Score Predictive Performance in Cancer Groups vs Matched Controls for CVD 2

The AUC, balanced accuracy, and sensitivity for the broader CVD endpoint (CVD 2) are compared between cancer groups and their matched control cohorts. Different cancer groups are listed on the right-hand side, whereas candidate CVD risk scores are shown on the left-hand side. Predictive performance results for cancer survivors are displayed in red, with matched controls in dark blue. Cancer groups not significantly different from their noncancer control group are shown in the lighter color. AUC results are from time-dependent analyses accounting for the competing risk of death at the 10-year follow-up. Balanced accuracy and sensitivity are from static performance scoring of 10-year outcomes, with 95% CIs derived from bootstrapping and permutation testing with 1,000 replicates. CVD 2 includes nonfatal myocardial infarction, nonfatal stroke, cardiovascular mortality, atrial fibrillation, heart failure, nonischemic cardiomyopathies, and valvular heart disease. Abbreviations as in Figures 1 and 2.